Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MXCT vs BVS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BVS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)
BVS Overall Winner
6-Pillar Tally: MXCT 1 – 5 BVS
Matrix Metrics: MXCT 2 – 8 BVS
As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas BVS carries 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin).
- Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. MXCT 41.7/100 SELL) and 0.85β · 74% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile BVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MXCT vs BVS
MXCT
MaxCyte, Inc. Common Stock
$1.37
+7.03% 1D
Market Cap
$132.2M
TTM Revenue
$34M
Forward P/E
N/M
Beta / 30D Vol
1.19β · 96% Vol
Unified Composite Score
41.7
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
BVS
Head-to-Head Winner
Bioventus Inc. Class A Common Stock
$9.88
-0.7% 1D
Market Cap
$681.3M
TTM Revenue
$586M
Forward P/E
11.1x
Beta / 30D Vol
0.85β · 74% Vol
Unified Composite Score
46.2
HOLD
Tech 35.0
Fund 49.0
Flow 64.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (MXCT 1 – 5 BVS)
1. Valuation Multiples
BVS
Forward P/E
N/M
11.1x
Trailing P/E
N/M
12.3x
PEG Ratio
N/M
1.20x
EV / Revenue
3.9x
1.5x
2. Growth & Scale
BVS
Revenue Growth (YoY)
+48.7%
+2.7%
Earnings Growth (YoY)
+0.0%
+69.7%
TTM Revenue (USD)
$34M
$586M
Market Cap
$132.2M
$681.3M
3. Profitability & Quality
BVS
Gross Margin
81.0%
68.7%
Operating Margin
-85.5%
10.1%
Net Profit Margin
-81.4%
9.8%
Return on Equity (ROE)
-16.9%
25.8%
4. Balance Sheet & Cash Flow
BVS
Cash Generation (TTM)
-$24M
$85M
Cash Flow Margin
-69.2%
14.5%
Net Cash / Leverage
$2.2M Net Debt (0.11x D/E)
$199M Net Debt (0.96x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MXCT
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
448.1% (100th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
BVS
OpEx & R&D Intensity
N/A
58.6% of Rev ($343M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MXCT (2) vs BVS (8)| Institutional Metric | MXCT | BVS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $132.2M | $681.3M | BVS | |
| Trailing P/E Ratio | N/M | 12.3x | BVS | |
| Forward P/E Ratio | N/M | 11.1x | BVS | |
| Revenue Growth (YoY) | +48.7% | +2.7% | MXCT | |
| Operating Margin (TTM) | -85.5% | 10.1% | BVS | |
| Net Profit Margin | -81.4% | 9.8% | BVS | |
| Return on Equity (ROE) | -16.9% | 25.8% | BVS | |
| 52-Week Range Position | 63% ($1–$2) | 36% ($6–$16) | MXCT | |
| Beta / 30D Volatility | 1.19β · 96% Vol | 0.85β · 74% Vol | BVS | |
| Unified Institutional Score | 41.7 / 100 (SELL) | 46.2 / 100 (HOLD) | BVS | |
| Trailing 12M Revenue (USD) | $34M | $586M | Scale | |
| Gross Profit Margin (TTM) | 81.0% | 68.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.9x EV/Rev | 1.20x PEG · 1.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$24M ($2.2M Net Debt (0.11x D/E)) | $85M ($199M Net Debt (0.96x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MXCT +30.11 pp
3M Horizon
MXCT +28.09 pp
6M Horizon
MXCT +25.26 pp
1Y Horizon
BVS +66.43 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MXCT Revenue | BVS Revenue | MXCT Op. Margin | BVS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $340M | -93.7% | 9.2% | BVS |
| FY2020 | $20M | $320M | -71.6% | 6.6% | BVS |
| FY2021 | $20M | $430M | -84.3% | 2.8% | BVS |
| FY2022 | $30M | $510M | -95.2% | -32.7% | BVS |
| FY2023 | $20M | $510M | -247.7% | -16.0% | BVS |
| FY2024 | $20M | $570M | -230.5% | -2.7% | BVS |
| FY2025 | $20M | $570M | -247.6% | 9.5% | BVS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MXCT
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BVS
BREAKDOWN
Current IV
448.1%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact BVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MXCT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
BVS Moat Profile
Scale & Operating Efficiency Moat
Medical Devices Operator
OpEx & R&D Reinvestment
58.6% of Rev ($343M)
90D Engineering Disclosures
0 Published
Investor FAQ MXCT vs BVS Key Questions & Quantitative Answers
As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas BVS carries 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin). Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. MXCT 41.7/100 SELL) and 0.85β · 74% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile BVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BVS leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with BVS at +2.7% YoY revenue growth and +69.7% YoY earnings growth on $586M TTM revenue (68.7% gross margin, 10.1% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MXCT cumulative revenue shifted +100.0% while BVS shifted +67.6%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus 58.6% of Rev ($343M) (0 disclosures) for BVS.
BVS screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas BVS trades at 11.1x Forward P/E, 12.3x Trailing P/E, 1.20x PEG, and 1.5x EV/Revenue (14.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus BVS (25.8% ROE) capital efficiency.
In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, BVS carries 448.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 74% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BVS vs MXCT · Reverse Pair
MXCT vs CTKB
· Sector Peer
MXCT vs SGHT
· Sector Peer
MXCT vs TMCI
· Sector Peer
BVS vs AVAH
· Sector Peer
BVS vs ANNX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem